Artiva Biotherapeutics Inc
ARTVBuild a strategy around ARTV
Artiva Biotherapeutics Inc AI Insights
Informational only. Not investment advice.Snapshot
- Trading at 0.63x book value (80.8M market cap vs 129.2M equity) - market pricing in significant failure risk despite 118.4M working capital buffer[Price to Book Ratio]
- Cash burn of 76.7M TTM with only 25.5M cash remaining implies ~4 months runway without dilutive financing[Cash Flow TTM]
- R&D spend of 65.9M TTM represents 76% of operating expenses - pure clinical-stage biotech with no revenue[Research and Development TTM]
Watch Triggers
- Cash and Equivalents: Falls below 15M or rises above 50M — Below 15M signals emergency financing; above 50M indicates completed raise
- Issuance of Capital Stock TTM: Any value above 0 — Signals dilutive financing has begun - watch terms for valuation impact
- Research and Development TTM: Drops below 50M or rises above 80M — Decline may signal trial pause/failure; increase suggests advancement
Bull Case
Deep discount to tangible book (0.63x P/B) with 118.4M working capital provides downside cushion if pipeline advances or partnership materializes
Minimal debt (9% D/E, 11.7M total) preserves financing flexibility for equity raise or strategic deal without creditor constraints
Bear Case
Zero revenue biotech burning 77M/year with only 4 months cash runway - dilution or failure highly probable without near-term catalyst
ROE of -50% and ROA of -44% TTM with no path to profitability visible - pure binary clinical bet
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage ARTV's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Imminent capital raise required within 6 months - dilution or partnership announcement likely catalyst
- 25.5M cash vs 76.7M annual burn rate
- Zero revenue with ongoing clinical trials
- No recent stock issuance (0 TTM)
Valuation Context
Caveats
ARTV Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$242.72M | — | ||
$232.03M | — | ||
0.00 | — | ||
$0 | — | ||
$-3.55 | — | ||
0% | — | ||
0% | — | ||
$-80.18M | — | ||
-67.9% | — | ||
Beta 5Y (Monthly) | unknown | — |
ARTV Dividend History
ARTV Stock Splits
ARTV SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
05/08/26 | 03/31/26 | 10-Q | |
03/10/26 | 12/31/25 | 10-K | |
11/12/25 | 09/30/25 | 10-Q | |
08/06/25 | 06/30/25 | 10-Q | |
05/08/25 | 03/31/25 | 10-Q | |
03/24/25 | 12/31/24 | Unknown | |
11/12/24 | 09/30/24 | 10-Q | |
08/29/24 | 06/30/24 | 10-Q | |
07/22/24 | 03/31/24 | 424B4 | |
07/22/24 | 12/31/23 | 424B4 | |
11/12/24 | 09/30/23 | 10-Q | |
08/29/24 | 06/30/23 | 10-Q | |
07/22/24 | 03/31/23 | 424B4 | |
06/06/22 | 03/31/22 | S-1/A | |
03/07/22 | 12/31/21 | S-1/A | |
01/21/22 | 09/30/21 | S-1/A | |
06/06/22 | 03/31/21 | S-1/A | |
01/21/22 | 12/31/20 | S-1/A |